Earlier diagnosis and treatment prevent complications.
Read More »T2DM Medications: All-Star Team Lineup
A recently published meta-analysis puts metformin to the test to see how well it lines up against other T2DM “Medication All-Star Team” members.
Read More »Empagliflozin Outcome on Obstructive Sleep Apnea, Cardiovascular, and Renal Events
The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.
Read More »Sotagliflozin: Implications in Patients Living With Chronic Kidney Disease
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Role of Magnesium in Type 2 Diabetes and Stroke
Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents.
Read More »Associations between Prediabetes and Vascular Complications
Do patients with prediabetes share the same vascular complication risk seen in patients with T2D?
Read More »Dulaglutide Can Reduce Cognitive Impairment in Patients with T2D
A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.
Read More »Prolonged Use of Proton Pump Inhibitors Linked to Increased Risk of T2DM
Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users.
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Telehealth, Smartphones, Mobile Apps and CGM: Changing The Way We Control Type 2 Diabetes In Adults
Can a virtual diabetes clinic (VDC) improve diabetes care?
Read More »